Please login to the form below
Sotorasib
This page shows the latest Sotorasib news and features for those working in and with pharma, biotech and healthcare.
Amgen announces positive results for Lumakras colorectal cancer combination treatment
Amgen’s Lumakras (sotorasib) combined with Vectibix (panitumumab) demonstrated ‘encouraging efficacy and safety’ in patients with KRAS G12C-mutated colorectal cancer (CRC), updated data from the company’s phase 1b CodeBreaK
Latest news
-
Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer
Amgen has announced that its phase 3 trial evaluating once daily oral Lumakras (sotorasib) met its primary endpoint of progression-free survival, demonstrating ‘statistical significance and superiority' over standard of care
-
NICE recommends Amgen’s Lumykras for non-small-cell lung cancer
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Amgen’s Lumykras (sotorasib) for treatment use within the Cancer Drugs Fund. ... However, the advances in new treatments like sotorasib
-
Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer
Amgen has announced trial results evaluating the safety and effectiveness of its drug Lumakras (sotorasib) that will be presented on 15 February at the monthly American Society of Clinical Oncology (ASCO) ... In the largest dataset evaluating the
-
Amgen’s Lumykras receives conditional marketing authorisation from EC
The European Commission (EC) has granted conditional marketing approval for Amgen’s Lumykras/Lumakras (sotorasib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the ... The CodeBreaK clinical development
-
Green light for Amgen’s KRAS inhibitor in the UK
Amgen’s first-in-class KRAS inhibitor sotorasib has been approved in the UK under a deal between the drug maker and NHS England. ... Sotorasib is one of the most exciting breakthroughs in lung cancer in 20 years,” said the charity’s chief clinician,
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Why you should feel optimistic about the future of healthcare
Precision medicines already exist; imatinib works to treat leukaemia only when the cancer cells have a particular genetic makeup, Sotorasib targets a specific mutation in people with lung cancer to halt
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
